Vaxxinity, Inc.

Market Cap $12.65K
PE -0
Debt $NaN
Cash $5.04M
EV $NaN
FCF -$58.04M

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	-$56.93M
EBIT	-$56.93M
ROE	-425%
ROA	-128%
FCF	-$58.04M
Equity	$13.41M
Growth Stability	1
PE	-0
PB	0
P/FCF	-0
Price/Cash	398.07
Equity CAGR	-59%
Earnings Growth YoY	-44%

Earnings Growth QoQ	-13%
Equity CAGR 5Y	-59%
Equity CAGR 3Y	-66%
Market Cap	$12.65K
Assets	$44.31M
Cash	$5.04M
Shares Outstanding	126.51M
Working Capital	15.63M
Current Ratio	1.89
Shares Growth 3y	9%
Equity Growth QoQ	-43%
Equity Growth YoY	-78%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

Vaxxinity Inc is engaged in the development and commercialization of prophylactic and therapeutic vaccines to combat chronic disorders and infectious diseases with large patient populations and unmet medical needs. Its pipeline primarily consists of five programs focused on chronic disease, particularly neurodegenerative disorders, in addition to other neurology and cardiovascular indications.

SEC Filings

Direct access to Vaxxinity, Inc. (VAXX) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2023
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2022
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2021
- 10-K Dec 31
- 10-Q Sep 30

Sector Comparison

How does Vaxxinity, Inc. compare to its competitors?

Not enough data to generate a comparison chart between Vaxxinity, Inc. and its competitors. Please check back later.

Peter Lynch's Chart

This chart shows the current pricing of Vaxxinity, Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

loading chart...

Vaxxinity, Inc. Discounted Cash Flow

Fully customizable DCF calculator online for Vaxxinity, Inc..

Years

Calculation mode

= -$580M

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	-$58M	-$58M	-$58M	-$58M	-$58M	-$58M	-$58M	-$58M	-$58M	-$58M	-$58M	-$580M
DCF		-$53M	-$48M	-$44M	-$40M	-$36M	-$33M	-$30M	-$27M	-$25M	-$22M	-$224M
Value	-$580M

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	12/2020	12/2021	12/2022	12/2023	TTM
Net Margins	-7K%	-208K%	-	-	-
ROA	-	-75%	-71%	-128%	-128%
ROE	-	-107%	-121%	-425%	-425%

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	12/2020	12/2021	12/2022	12/2023	TTM
Debt over FCF	-	-1.7	-0.48	-	-
Debt over Equity	-0.28	1.09	0.45	-	-
Growth Stability	-	-	-	-	1

Neutral Debt/FCF ratio (-)

Net Margins are at a level that is not too high nor too low. They are not a competitive advantage but they are not a competitive disadvantage either.

Neutral Debt/Equity ratio (-)

The company has a balance between equity and debt that is not too good nor too bad.

Good Graham’s Stability (1)

The company has a good stability in its earnings, which is a sign of a good competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	12/2020	12/2021	12/2022	12/2023	CAGR 5Y
Revenue YoY growth	-	-88%	-100%	-	-
Earnings YoY growth	-	243%	-45%	-24%	-
Equity YoY growth	-	-247%	-52%	-78%	-59%
FCF YoY growth	-	133%	-30%	0%	-